Recent trading patterns in the stock of Immunomedics, Inc. (NASDAQ:IMMU) have investors on high alert. Traders use price and volume data to predict performance and time their positions. In the case of IMMU, the data could have some important implications for future performance. In the most recent quarter, institutional ownership increased by a net of 18.74 million shares, or 21.6%.This is a bullish sign and indicates that institutions are feeling more optimistic about the outlook for IMMU overall.78 holders increased their positions, 60 decreased their positions, and 12 holders held their positions.

Among institutions that increased their positions, 27 were new positions. Among holders that decreased their positions, 21 sold out of the stock Immunomedics, Inc.. Insider ownership during the latest quarter decreased by a net of 184406 shares, indicating that IMMU’s key executives are feeling more bearish about the stock than they did three months ago. 4 or 20% of the trades during the past quarter were buys, and 16 or 80% were sells. This activity represents a continuation of a theme over the past twelve months. Insider ownership during the last year has decreased by a net of 199549 shares. 17.39% of insider trades in the last 12 months were buys, and 82.61% were sells.

Over the past year, the price of Immunomedics, Inc. (IMMU) has increased 370.80% while the S&P 500 has increased 19.49%. During the past 20 days, IMMU has decreased -2.65% while the broad market has increased 1.94%. IMMU ‘s 20-day moving average currently sits below its 100-day moving average. This is a bearish signal that suggests the stock price might have farther to fall. IMMU’s average trading volume during the past 20 days is lower than the average volume over the past 100 days, which could be an indication that investors are feeling less certain than usual about the direction of IMMU’s future price movements.



Immunomedics, Inc. (NASDAQ:IMMU) has a 20-day RSI of 50.96%. According to this momentum indicator, a reading between 30 and 70 suggests the stock is not especially cheap or expensive, and not on the brink of a trend reversal. The MACD tells a different story. IMMU’s 9-day MACD currently sits below the 20-day MACD, indicating that IMMU’s downside momentum has decreased during the last three weeks. This suggests that the trend might soon reverse. IMMU’s average trading volatility during the past few weeks is 8.84% higher than the average volatility over the past 100 days. This means that the stock’s daily price swings have been more extreme in recent times compared to the past.

Analysts expect Immunomedics, Inc. (IMMU) to generate earnings per share of $0.41 in 2017. This works out to a decrease of -49.38% compared to last year’s earnings. For comparison’s sake, analysts expect the S&P 500 to grow earnings by an average of 12% in 2017. The average investment rating for IMMU on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 5.00 or a Strong Buy. Three months ago, analysts assigned IMMU a 5.00 rating, which implies that analysts largely still feel the same about the outlook for the stock over the next year.